含克力芝HAART方案引起高脂血症临床干预的研究

发布时间：2018-05-15 04:08

本文选题：克力芝 + 阿托伐他汀　；参考：《中国艾滋病性病》2015年01期

【摘要】：目的比较阿托伐他汀与血脂康胶囊对含克力芝抗病毒治疗方案引起的高脂血症的疗效,探讨此类高脂血症的治疗方法。方法将60例使用含克力芝抗病毒治疗方案引起高脂血症的患者,随机分为观察组和对照组,每组各30例。观察组给予阿托伐他汀治疗,对照组给予血脂康胶囊治疗。治疗24周后比较两组的总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)的水平。结果观察组降血脂的总有效率为93.3%(28/30),高于对照组的46.7%(14/30),差异有统计学意义(P0.05)。24周疗程结束后,2组血清TC、TG、LDL-C水平均低于治疗前,HDL-C高于治疗前,且观察组优于对照组,差异有统计学意义(P0.05)。结论与血脂康胶囊相比,在抗病毒治疗中使用阿托伐他汀可更为有效地控制由克力芝抗病毒治疗方案引起的高脂血症,值得临床推广使用。
[Abstract]:Objective to compare the therapeutic effects of Atto vastatin and Xuezhikang capsule on hyperlipidemia induced by anti-viral therapy of clozidium and to explore the treatment methods of such hyperlipidemia. Methods 60 patients with hyperlipidemia caused by antiviral therapy were randomly divided into observation group and control group with 30 cases in each group. The observation group was treated with Atto vastatin and the control group with Xuezhikang capsule. After 24 weeks of treatment, the levels of TC, TG, HDL-C, LDL-C were compared between the two groups. Results the total effective rate of reducing blood lipid in the observation group was 93.30.28% 30%, which was higher than that in the control group (46.7%). The difference was statistically significant (P 0.05). The LDL-C level of serum TCU TGN in the two groups was lower than that before treatment and higher than that before treatment, and the observation group was superior to the control group (P 0.05). Conclusion compared with Xuezhikang capsule, the use of Atto vastatin in antiviral therapy is more effective in controlling hyperlipidemia caused by the antiviral therapy regimen, and it is worth popularizing in clinic.
【作者单位】：广西贺州市人民医院;
【分类号】：R512.91;R589.2

【相似文献】